Authors:
MAUGER C
SIVAN B
BROCKHAUS M
FUCHS S
CIVELLI O
MONSMA F
Citation: C. Mauger et al., DEVELOPMENT AND CHARACTERIZATION OF ANTIBODIES DIRECTED AGAINST THE MOUSE D4 DOPAMINE-RECEPTOR, European journal of neuroscience, 10(2), 1998, pp. 529-537
Citation: O. Civelli et al., REVERSE PHYSIOLOGY - DISCOVERY OF THE NOVEL NEUROPEPTIDE, ORPHANIN FQNOCICEPTIN, Critical reviews in neurobiology, 12(3), 1998, pp. 163-176
Authors:
MENG F
UEDA Y
HOVERSTEN MT
TAYLOR LP
REINSCHEID RK
MONSMA FJ
WATSON SJ
CIVELLI O
AKIL H
Citation: F. Meng et al., CREATING A FUNCTIONAL OPIOID ALKALOID BINDING-SITE IN THE ORPHANIN FQRECEPTOR THROUGH SITE-DIRECTED MUTAGENESIS, Molecular pharmacology, 53(4), 1998, pp. 772-777
Authors:
FERRE S
TORVINEN M
ANTONIOU K
IRENIUS E
CIVELLI O
ARENAS E
FREDHOLM BB
FUXE K
Citation: S. Ferre et al., ADENOSINE A(1) RECEPTOR-MEDIATED MODULATION OF DOPAMINE D-1 RECEPTORSIN STABLY COTRANSFECTED FIBROBLAST CELLS, The Journal of biological chemistry, 273(8), 1998, pp. 4718-4724
Authors:
REINSCHEID RK
HIGELIN J
HENNINGSEN RA
MONSMA FJ
CIVELLI O
Citation: Rk. Reinscheid et al., STRUCTURES THAT DELINEATE ORPHANIN FQ AND DYNORPHIN-A PHARMACOLOGICALSELECTIVITIES, The Journal of biological chemistry, 273(3), 1998, pp. 1490-1495
Authors:
ZENNER MT
NOBILE M
HENNINGSEN R
SMERALDI E
CIVELLI O
HARTMAN DS
CATALANO M
Citation: Mt. Zenner et al., EXPRESSION AND CHARACTERIZATION OF A DOPAMINE D4R VARIANT ASSOCIATED WITH DELUSIONAL DISORDER, FEBS letters, 422(2), 1998, pp. 146-150
Authors:
CIVELLI O
NOTHACKER HP
BOURSON A
ARDATI A
MONSMA F
REINSCHEID R
Citation: O. Civelli et al., ORPHAN RECEPTORS AND THEIR NATURAL LIGANDS, Journal of receptor and signal transduction research, 17(1-3), 1997, pp. 545-550
Authors:
JENCK F
MOREAU JL
MARTIN JR
KILPATRICK GJ
REINSCHEID RK
MONSMA FJ
NOTHACKER HP
CIVELLI O
Citation: F. Jenck et al., ORPHANIN FQ ACTS AS AN ANXIOLYTIC TO ATTENUATE BEHAVIORAL-RESPONSES TO STRESS, Proceedings of the National Academy of Sciences of the United Statesof America, 94(26), 1997, pp. 14854-14858
Authors:
ARDATI A
HENNINGSEN RA
HIGELIN J
REINSCHEID RK
CIVELLI O
MONSMA FJ
Citation: A. Ardati et al., INTERACTION OF [H-3] ORPHANIN FQ AND I-125 TYR14-ORPHANIN FQ WITH THEORPHANIN FQ RECEPTOR - KINETICS AND MODULATION BY CATIONS AND GUANINE-NUCLEOTIDES, Molecular pharmacology, 51(5), 1997, pp. 816-824
Citation: F. Lanau et al., EPINEPHRINE AND NOREPINEPHRINE ACT AS POTENT AGONISTS AT THE RECOMBINANT HUMAN DOPAMINE D4 RECEPTOR, Journal of neurochemistry, 68(2), 1997, pp. 804-812
Citation: Ds. Hartman et O. Civelli, MOLECULAR ATTRIBUTES OF DOPAMINE-RECEPTORS - NEW POTENTIAL FOR ANTIPSYCHOTIC DRUG DEVELOPMENT, Annals of medicine, 28(3), 1996, pp. 211-219
Authors:
DEVINE DP
TAYLOR L
REINSCHEID RK
MONSMA FJ
CIVELLI O
AKIL H
Citation: Dp. Devine et al., RATS RAPIDLY DEVELOP TOLERANCE TO THE LOCOMOTOR-INHIBITING EFFECTS OFTHE NOVEL NEUROPEPTIDE ORPHANIN FQ, Neurochemical research, 21(11), 1996, pp. 1387-1396
Authors:
KNOFLACH F
REINSCHEID RK
CIVELLI O
KEMP JA
Citation: F. Knoflach et al., MODULATION OF VOLTAGE-GATED CALCIUM CHANNELS BY ORPHANIN FQ IN FRESHLY DISSOCIATED HIPPOCAMPAL-NEURONS, The Journal of neuroscience, 16(21), 1996, pp. 6657-6664
Authors:
NOTHACKER HP
REINSCHEID RK
MANSOUR A
HENNINGSEN RA
ARDATI A
MONSMA FJ
WATSON SJ
CIVELLI O
Citation: Hp. Nothacker et al., PRIMARY STRUCTURE AND TISSUE DISTRIBUTION OF THE ORPHANIN FQ PRECURSOR, Proceedings of the National Academy of Sciences of the United Statesof America, 93(16), 1996, pp. 8677-8682
Authors:
KNOFLACH F
REINSCHEID RK
CIVELLI O
KEMP JA
Citation: F. Knoflach et al., ORPHANIN FQ INHIBITION OF VOLTAGE-GATED CALCIUM CHANNELS IN RAT HIPPOCAMPAL CA3 NEURONS IN-VITRO, Journal of physiology, 494P, 1996, pp. 55-55
Authors:
MENG F
TAYLOR LP
HOVERSTEN MT
UEDA Y
ARDATI A
REINSCHEID RK
MONSMA FJ
WATSON SJ
CIVELLI O
AKIL H
Citation: F. Meng et al., MOVING FROM THE ORPHANIN FQ RECEPTOR TO AN OPIOID RECEPTOR USING 4 POINT MUTATIONS, The Journal of biological chemistry, 271(50), 1996, pp. 32016-32020
Authors:
DEVINE DP
REINSCHEID RK
MONSMA FJ
CIVELLI O
AKIL H
Citation: Dp. Devine et al., THE NOVEL NEUROPEPTIDE ORPHANIN FQ FAILS TO PRODUCE CONDITIONED PLACEPREFERENCE OR AVERSION, Brain research, 727(1-2), 1996, pp. 225-229
Authors:
BOUVIER C
BUNZOW JR
GUAN HC
UNTEUTSCH A
CIVELLI O
GRANDY DK
VANTOL HHM
Citation: C. Bouvier et al., FUNCTIONAL-CHARACTERIZATION OF THE HUMAN DOPAMINE D-4.2 RECEPTOR USING VACCINIA VIRUS AS AN EXPRESSION SYSTEM, European journal of pharmacology. Molecular pharmacology section, 290(1), 1995, pp. 11-17
Authors:
REINSCHEID RK
NOTHACKER HP
BOURSON A
ARDATI A
HENNINGSEN RA
BUNZOW JR
GRANDY DK
LANGEN H
MONSMA FJ
CIVELLI O
Citation: Rk. Reinscheid et al., ORPHANIN-FQ - A NEUROPEPTIDE THAT ACTIVATES AN OPIOID-LIKE G-PROTEIN-COUPLED RECEPTOR, Science, 270(5237), 1995, pp. 792-794
Authors:
MEADORWOODRUFF JH
GRANDY DK
VANTOL HHM
DAMASK SP
LITTLE KY
CIVELLI O
WATSON SJ
Citation: Jh. Meadorwoodruff et al., DOPAMINE-RECEPTOR GENE-EXPRESSION IN THE HUMAN MEDIAL TEMPORAL-LOBE, Neuropsychopharmacology, 10(4), 1994, pp. 239-248
Authors:
SAEZ C
ZHOU QY
CIVELLI O
BUNZOW JR
GRANDY DK
Citation: C. Saez et al., DISTRIBUTION OF MESSENGER-RNA ENCODING A NOVEL OPIOID RECEPTOR IN MOUSE-BRAIN, Regulatory peptides, 1994, pp. 190000013-190000014